Clinical Trials Logo

Beta-Thalassemia clinical trials

View clinical trials related to Beta-Thalassemia.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04938635 Withdrawn - Beta-Thalassemia Clinical Trials

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

Start date: September 20, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of 3 multiple doses of VIT-2763 as measured by the reduction in red blood cell (RBC) transfusion burden from Week 13 to Week 24, to identify the most efficacious and safe dose.

NCT ID: NCT04776850 Withdrawn - Sickle Cell Disease Clinical Trials

Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies

Start date: December 29, 2020
Phase: Early Phase 1
Study type: Interventional

This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies). PTIS helps prepare the body for the transplant and lowers the risk of developing graft versus host disease (GVHD). Hematopoietic cells are found in the bone marrow and produce blood cells. Hematopoietic cell transplantation (HCT) injects healthy hematopoietic cells into the body to support blood cell production. PTIS and HCT may help to control severe hemoglobinopathies.

NCT ID: NCT04176653 Withdrawn - Clinical trials for Non-transfusion-dependent Thalassemia

Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124

Start date: August 20, 2019
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine the safety and tolerability of SLN124 for the treatment of non-transfusion-dependent (NTD) β-thalassaemia and low risk myelodysplastic syndrome.

NCT ID: NCT03801889 Withdrawn - Iron Overload Clinical Trials

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Start date: August 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the safety and tolerability of SP-420 and it's efficacy in terms of lowering iron in subjects with Beta-thalassemia or other rare anemias who need regular blood transfusions.

NCT ID: NCT01927913 Withdrawn - Metabolic Diseases Clinical Trials

Treatment of Iron Overload Requiring Chelation Therapy

Start date: November 20, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this open-label study is to assess liver iron concentration using MRI imaging in subjects with beta-thalassemia when administered with either SPD602 or deferasirox for the treatment of chronic transfusional iron overload.

NCT ID: NCT01724138 Withdrawn - ß-thalassemia Major Clinical Trials

An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old

MACS2163
Start date: June 2013
Phase: Phase 4
Study type: Interventional

To characterize the PK of deferasirox in pediatric β-thalassemia major patients aged from 2 to less than 6 years old, when administrated with a fixed starting dose of 20 mg/kg/day.

NCT ID: NCT01419704 Withdrawn - Thalassemia Clinical Trials

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

Start date: May 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with hemoglobinopathies.